Lab Home | Phone | Search
	Center for Nonlinear Studies
	Home  ▶ People   Current   Executive Committee   Postdocs   Visitors   Students   Research   Publications  ▶ Conferences   Workshops   Sponsorship  ▶ Talks   Seminars   Postdoc Seminars Archive   Quantum Lunch   Quantum Lunch Archive   P/T Colloquia   Archive   Ulam Scholar     Postdoc Nominations  ▶ Student Requests   Student Program  ▶ Visitor Requests   Description   Past Visitors  ▶ Services   General     History of CNLS     Maps, Directions   CNLS Office   T-Division   LANL				Friday, September 29, 201711:00 AM - 12:00 PMCNLS Conference Room (TA-3, Bldg 1690) Seminar Entasis' efforts on Gram-negative Drug Discovery Dr. Ruben TommasiChief Scientific Officer of Entasis Therapeutics Topic: Entasi efforts on Gram-negative Drug Discovery Non-confidential summary of our company and pipeline Our efforts to better understand Gram-negative uptake Speaker Bio: Ruben Tommasi is the Chief Scientific Officer of Entasis Therapeutics. Dr. Tommasi was the head of infectious disease chemistry at Norvartis and Astra Zeneca before the current appointment. Entasis was established in 2015 with start-up funding from Astra Zeneca (AZ) with all rights to AZ. Currently, Entasis is a leading companies and it relies on computations for drug discovery. Their drug discovery platform combines genetic tools, molecular dynamics simulations and modeling. Host: Gnana Gnanakaran